Home  /   Products  /   Cardiovascular  /   Moxonidine (Physiotens) 0.2 mg – [28 tablets]
Moxonidine (Physiotens) 0.2 mg - [28 tablets]

Moxonidine (Physiotens) 0.2 mg – [28 tablets]

$27.32

Centrally acting hypotensive agent

Administration of Moxonidine (Physiotens) 0.2 mg leads to a decrease in systemic vascular resistance and blood pressure. The initial dose is 0.2 mg per day.

SKU: 63129 Category:

Description

Moxonidine (Physiotens) 0.2 mg Pharmacodynamics
Moxonidine is a hypotensive agent with a central mechanism of action.
In brain stem structures (rostral layer of lateral ventricles) moxonidine selectively stimulates imidazoline-sensitive receptors involved in tonic and reflex regulation of sympathetic nervous system. Stimulation of imidazoline receptors reduces peripheral sympathetic activity and blood pressure (BP).
Moxonidine differs from other sympatholytic hypotensive agents in its lower affinity for ?2-adrenoreceptors, which explains the lower probability of developing sedative effects and dry mouth.
Administration of moxonidine leads to a decrease in systemic vascular resistance and BP. The hypotensive effect of moxonidine has been confirmed in double-blind placebo-controlled randomized trials.
Results of a clinical trial involving 42 patients with arterial hypertension and left ventricular hypertrophy (LVH) demonstrated that with similar blood pressure reductions, use of a combination of angiotensin II receptor antagonists with moxonidine reduces LVH to a greater extent than the free combination of a thiazide diuretic and a calcium channel blocker (15% versus 11%; p < 0.05).
Moxonidine improves insulin sensitivity index by 21% (compared with placebo) in patients with obesity, insulin resistance, and moderate arterial hypertension.

 

Indications
Arterial hypertension.

 

Contraindications .
– Hypersensitivity to the active substance and other components of Moxonidine (Physiotens) 0.2 mg;
– history of angioedema;
– Sinus node weakness syndrome or sinoatrial blockade;
– severe hepatic insufficiency;
– Severe bradycardia (resting heart rate (HR) less than 50 bpm);
– Grade II or III atrioventricular block;
– Acute and chronic heart failure;
– Breast-feeding period;
– hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption;
– under 18 years of age (due to lack of data on efficacy and safety).

 

Dosage and administration method
  • Orally, regardless of meals.
  • In most cases, initial dose of Physiotens is 0.2 mg per day.
  • Maximal single dose is 0.4 mg.
  • Maximum daily dose to be divided into 2 intakes is 0.6 mg. Individual correction of daily dose is necessary depending on patient’s tolerance to the therapy.
  • No dose adjustment is required for patients with hepatic insufficiency.
  • The initial dose for patients on hemodialysis is 0.2 mg per day. In case of necessity and good tolerability the daily dose may be increased up to maximum 0.4 mg per day.
  • In patients with renal insufficiency, a cautious selection of the dose is recommended, especially at the beginning of treatment.
  • The initial dose should be 0.2 mg per day. If necessary and in case of good tolerability, daily dose of this medicine can be increased up to maximum 0.4 mg for patients with moderate renal insufficiency (CKD more than 30 ml/min, but less than 60 ml/min) and 0.3 mg for patients with severe renal insufficiency (CKD less than 30 ml/min).

Related products